Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19 : A Case Report and Literature Review
BACKGROUND: Although remdesivir treatment is widely used during the pandemic coronavirus disease 2019 (COVID-19), there is scarce evidence regarding its cardiac side effects.
CASE PRESENTATION: We report the case of a 36-year-old male hospitalized due to severe COVID-19 symptoms. He presented with a 10-day history of fever (up to 39.7 °C), productive cough, hemoptysis, fatigue, myalgias and hypoxemia. The patient received supplemental oxygen, dexamethasone, remdesivir and empirical antibiotic treatment according to protocol. Asymptomatic sinus bradycardia developed on hospital day 3 (namely, heart rate 39/min compared to 92/min on admission). Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. The patient's rhythm restored to normal 9 days after the discontinuation of remdesivir.
CONCLUSIONS: Considering the frequent use of remdesivir in patients with COVID-19, physicians should be aware of this possible adverse event.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of cardiovascular development and disease - 8(2021), 2 vom: 12. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barkas, Fotios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arrhythmia |
|---|
| Anmerkungen: |
Date Revised 16.03.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcdd8020018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322304997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322304997 | ||
| 003 | DE-627 | ||
| 005 | 20231225181746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcdd8020018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322304997 | ||
| 035 | |a (NLM)33673216 | ||
| 035 | |a (PII)18 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barkas, Fotios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19 |b A Case Report and Literature Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Although remdesivir treatment is widely used during the pandemic coronavirus disease 2019 (COVID-19), there is scarce evidence regarding its cardiac side effects | ||
| 520 | |a CASE PRESENTATION: We report the case of a 36-year-old male hospitalized due to severe COVID-19 symptoms. He presented with a 10-day history of fever (up to 39.7 °C), productive cough, hemoptysis, fatigue, myalgias and hypoxemia. The patient received supplemental oxygen, dexamethasone, remdesivir and empirical antibiotic treatment according to protocol. Asymptomatic sinus bradycardia developed on hospital day 3 (namely, heart rate 39/min compared to 92/min on admission). Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. The patient's rhythm restored to normal 9 days after the discontinuation of remdesivir | ||
| 520 | |a CONCLUSIONS: Considering the frequent use of remdesivir in patients with COVID-19, physicians should be aware of this possible adverse event | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a arrhythmia | |
| 650 | 4 | |a bradycardia | |
| 650 | 4 | |a remdesivir | |
| 700 | 1 | |a Styla, Chrysoula-Paraskevi |e verfasserin |4 aut | |
| 700 | 1 | |a Bechlioulis, Aris |e verfasserin |4 aut | |
| 700 | 1 | |a Milionis, Haralampos |e verfasserin |4 aut | |
| 700 | 1 | |a Liberopoulos, Evangelos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular development and disease |d 2014 |g 8(2021), 2 vom: 12. Feb. |w (DE-627)NLM248446517 |x 2308-3425 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:2 |g day:12 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcdd8020018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 2 |b 12 |c 02 | ||